Mdxhealth Sa (MXDHF) 5.5000 $MXDHF
MDxHealth Provides First Quarter 2015 Business Update
GlobeNewswire - Tue May 05, 1:13AM CDT
ConfirmMDx Test Revenue Increases 177% over First Quarter 2014
MDxHealth: Exploiting A Valuation Anomaly Between Exact Sciences And Their European Licensor
VMK Investment Research - at Seeking Alpha - Wed Apr 29, 4:31PM CDT
EXAS: 22.97 (-0.04)
MDxHealth Named Winner of Corporate LiveWire Innovation & Excellence 2015 Award
GlobeNewswire - Fri Apr 24, 2:18AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced today that it has been named as one of the winners of the Corporate LiveWire Innovation & Excellence Awards. The awards are in recognition of innovation and excellence that recipient companies, teams and individuals have shown amid ongoing global economic uncertainty.
MDxHealth Completes Enrollment of Second ConfirmMDx Clinical Utility Study
GlobeNewswire - Mon Apr 20, 1:03AM CDT
MDxHealth SA (Euronext: MDXH.BR) today announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx for Prostate Cancer. The study, which will evaluate the impact of the ConfirmMDx test results on physician decisions for repeat biopsy, enrolled 600 patients from 17 leading urology practices across the U.S.
MyCartis Announces Appointment of Dr. Jan Groen to Its Board of Directors
PR Newswire Europe - Thu Apr 09, 1:01AM CDT
GHENT, Belgium and LAUSANNE, Switzerland, April 9, 2015 /PRNewswire/ --
MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
GlobeNewswire - Mon Mar 02, 1:08AM CST
MDxHealth SA (Euronext: MDXH.BR), today announced that data demonstrating the prognostic value of its ConfirmMDx for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015 in Rosen Shingle Creek, Orlando, Florida, USA (February 26-28, 2015). The data support the ability to predict the presence of clinically significant cancer in biopsy-negative patients based on the DNA hypermethylation of the biomarkers in the ConfirmMDx test.
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 224.63 (+1.81), SLXP: 172.96 (+0.15), ICPT: 306.23 (-0.84), SPPI: 6.68 (-0.14), EXAS: 22.97 (-0.04)
MDxHealth Named Euronext Best BEL Small Company Performer for 2014
GlobeNewswire - Wed Jan 21, 1:05AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
MDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
GlobeNewswire - Wed Jan 14, 1:06AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
MDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
GlobeNewswire - Mon Jan 05, 1:04AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 18.04 (-0.18), TMO: 130.16 (-0.94), EXAS: 22.97 (-0.04)
MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
GlobeNewswire - Wed Nov 12, 2:35AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, which is being held on November 20, 2014, at Westin Grand Central in New York. Dr. Jan Groen will make the Company's presentation at 1:30 PM Eastern Daylight Time. The presentation will be posted under the investor tab of the MDxHealth website (http://mdxhealth.com/investors/shareholder-information) after the conference.
MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST
EXAS: 22.97 (-0.04)
MDxHealth Provides Third Quarter 2014 Business Update
GlobeNewswire - Tue Nov 04, 1:08AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.
MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
GlobeNewswire - Fri Oct 10, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.
MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
GlobeNewswire - Tue Oct 07, 1:09AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from a validation study of an epigenetic test to predict prostate cancer (PCa) aggressiveness at the European Association of Urology, Section Urological Research meeting in Glasgow, UK (October 9-11, 2014).
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
MDxHealth Provides First Quarter 2015 Business Update
GlobeNewswire - Tue May 05, 1:13AM CDT
ConfirmMDx Test Revenue Increases 177% over First Quarter 2014
MDxHealth: Exploiting A Valuation Anomaly Between Exact Sciences And Their European Licensor
VMK Investment Research - at Seeking Alpha - Wed Apr 29, 4:31PM CDT
EXAS: 22.97 (-0.04)
MDxHealth Named Winner of Corporate LiveWire Innovation & Excellence 2015 Award
GlobeNewswire - Fri Apr 24, 2:18AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced today that it has been named as one of the winners of the Corporate LiveWire Innovation & Excellence Awards. The awards are in recognition of innovation and excellence that recipient companies, teams and individuals have shown amid ongoing global economic uncertainty.
MDxHealth Completes Enrollment of Second ConfirmMDx Clinical Utility Study
GlobeNewswire - Mon Apr 20, 1:03AM CDT
MDxHealth SA (Euronext: MDXH.BR) today announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx for Prostate Cancer. The study, which will evaluate the impact of the ConfirmMDx test results on physician decisions for repeat biopsy, enrolled 600 patients from 17 leading urology practices across the U.S.
MyCartis Announces Appointment of Dr. Jan Groen to Its Board of Directors
PR Newswire Europe - Thu Apr 09, 1:01AM CDT
GHENT, Belgium and LAUSANNE, Switzerland, April 9, 2015 /PRNewswire/ --
MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
GlobeNewswire - Mon Mar 02, 1:08AM CST
MDxHealth SA (Euronext: MDXH.BR), today announced that data demonstrating the prognostic value of its ConfirmMDx for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015 in Rosen Shingle Creek, Orlando, Florida, USA (February 26-28, 2015). The data support the ability to predict the presence of clinically significant cancer in biopsy-negative patients based on the DNA hypermethylation of the biomarkers in the ConfirmMDx test.
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 224.63 (+1.81), SLXP: 172.96 (+0.15), ICPT: 306.23 (-0.84), SPPI: 6.68 (-0.14), EXAS: 22.97 (-0.04)
MDxHealth Named Euronext Best BEL Small Company Performer for 2014
GlobeNewswire - Wed Jan 21, 1:05AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
MDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
GlobeNewswire - Wed Jan 14, 1:06AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
MDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
GlobeNewswire - Mon Jan 05, 1:04AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.
Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST
VIVO: 18.04 (-0.18), TMO: 130.16 (-0.94), EXAS: 22.97 (-0.04)
MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
GlobeNewswire - Wed Nov 12, 2:35AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, which is being held on November 20, 2014, at Westin Grand Central in New York. Dr. Jan Groen will make the Company's presentation at 1:30 PM Eastern Daylight Time. The presentation will be posted under the investor tab of the MDxHealth website (http://mdxhealth.com/investors/shareholder-information) after the conference.
MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST
EXAS: 22.97 (-0.04)
MDxHealth Provides Third Quarter 2014 Business Update
GlobeNewswire - Tue Nov 04, 1:08AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.
MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
GlobeNewswire - Fri Oct 10, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.
MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
GlobeNewswire - Tue Oct 07, 1:09AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from a validation study of an epigenetic test to predict prostate cancer (PCa) aggressiveness at the European Association of Urology, Section Urological Research meeting in Glasgow, UK (October 9-11, 2014).
MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.
